NCT02491450View on ClinicalTrials.gov

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Healthy
Interventions
DRUG

Heterosofir

1 tablet contains 400 mg sofosbuvir

DRUG

Sovaldi

1 tablet contains 400 mg sofosbuvir

Trial Locations (1)

Unknown

Genuine Research Center GRC, Cairo

All Listed Sponsors
collaborator

Pharmed Healthcare, Egypt

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY

NCT02491450 - A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland) | Biotech Hunter | Biotech Hunter